Actuate Therapeutics Inc
ACTUHealthcare|Biotechnology|US
$0.33
+0.00 (+0.55%)
DCF Value
$0.54
Tangible Book / Share
$0.04
Cash / Share
$0.19
About
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
Stock Price
-94.7%(1Y)
1M
-51.6%
3M
-70.4%
6M
-90.0%
YTD
-94.6%
1Y
-94.4%
3Y
-96.2%
5Y
-96.2%
Pipeline Summary
11 total trials3
Phase 1
9
Phase 2
0
Phase 3
0
Phase 4
Terminated: 2Withdrawn: 3Completed: 1Recruiting: 1Active: 3Not Yet Recruiting: 1
Active Trials (4)
9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)
NCT06896188Pancreatic Adenocarcinoma
Phase 1Recruiting
Enrollment: 12 participants
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
NCT05010629Salivary Gland Cancer
Phase 2Active
Enrollment: 32 participants
FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer
NCT05077800Pancreatic Adenocarcinoma
Phase 2Active
Enrollment: 70 participants
9-ING-41 in Patients With Advanced Cancers
NCT03678883Cancer
Phase 2Active
Enrollment: 350 participants
Key Facts
Market Cap$7.9M
Employees12 (+20% YoY)
CEODaniel Schmitt
IPO DateAug 13, 2024
Beta0.78
52-Week Range$0.3006 – $7.9
Avg Volume416,979
ExchangeNASDAQ
Websiteactuatetherapeutics.com
Ownership
Float35.2%
Shares Outstanding24.0M
Recent Insider Trades
THOMSON TODD SAWARD
Oct 28, 2026269,017 shares @ $0.53
THOMSON TODD SAWARD
Oct 28, 2026259,572 shares @ $0.53
THOMSON TODD SAWARD
Oct 28, 202695,673 shares @ $0.53
THOMSON TODD SAWARD
Oct 28, 202675,738 shares @ $0.53
BIOS Fund III, LPAWARD
Oct 28, 2026824,012 shares @ $0.53
Peers
Recent News
Actuate Therapeutics to Present Promising Preclinical Data Demonstrating Antitumor and Immune Activation Activity of Elraglusib Oral Tablet in Advanced Melanoma Models at ENA 2026
Nov 4, 2026 · globenewswire.com
Actuate Therapeutics Receives U.S. Notice of Allowance for Patent Covering Elraglusib Oral Tablets
Nov 2, 2026 · globenewswire.com
Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering
Oct 27, 2026 · globenewswire.com
Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Sep 9, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 03:52 AM